FSSAI suspends licence of Dior Pharmaceuticals for violations at nutraceutical plant

New Delhi: Food regulator FSSAI has suspended the licence of Dior Pharmaceuticals for multiple violations at its nutraceutical factory.

In a social media post on Thursday, FSSAI observed “serious non-compliances” during the inspection of the manufacturing unit in Punjab.

“The Nutraceutical Manufacturing Unit was found to be operating under severely deficient Good Manufacturing Practices (GMP), Good Hygiene Practices (GHP), and Food Safety Management Systems (FSMS),” the Food Safety and Standards Authority of India (FSSAI) said.

Stating that the deficiencies pose a significant risk to public health, FSSAI said there has been a gross non-compliance with the FSS Act, 2006.

“The FSSAI Licence has been suspended with immediate effect. The FBO (food business operator) has been directed to immediately cease all operations until all deficiencies are rectified and compliance is established to the satisfaction of the Competent Authority,” the regulator said.

Giving details about major and critical non-conformities observed during the inspection, FSSAI said that the regulatory non-compliances were related to infrastructure; sanitation and housekeeping; pest control; storage and handling practices; process controls; personnel hygiene; water quality monitoring; and maintenance of records, among other issues.

The regulator further said that there is a serious failure on the part of the company in ensuring the safety, quality and traceability of food products.

In the last few months, FSSAI has cracked down on many energy drink and alcoholic beverage companies for misleading claims and labelling. It has also issued notices to many e-commerce platforms.

These actions are based on consumer complaints, suo motu cognisance, and regular enforcement activities of food safety officers.

FSSAI posts updates about these enforcement actions against food business operators and e-commerce companies through social media platforms, including Instagram.

“The Nutraceutical Manufacturing Unit was found to be operating under severely deficient Good Manufacturing Practices (GMP), Good Hygiene Practices (GHP), and Food Safety Management Systems (FSMS),” the Food Safety and Standards Authority of India (FSSAI) said.

Stating that the deficiencies pose a significant risk to public health, FSSAI said there has been a gross non-compliance with the FSS Act, 2006.

“The FSSAI Licence has been suspended with immediate effect. The FBO (food business operator) has been directed to immediately cease all operations until all deficiencies are rectified and compliance is established to the satisfaction of the Competent Authority,” the regulator said.

Giving details about major and critical non-conformities observed during the inspection, FSSAI said that the regulatory non-compliances were related to infrastructure; sanitation and housekeeping; pest control; storage and handling practices; process controls; personnel hygiene; water quality monitoring; and maintenance of records, among other issues.

The regulator further said that there is a serious failure on the part of the company in ensuring the safety, quality and traceability of food products.

In the last few months, FSSAI has cracked down on many energy drink and alcoholic beverage companies for misleading claims and labelling. It has also issued notices to many e-commerce platforms.

These actions are based on consumer complaints, suo motu cognisance, and regular enforcement activities of food safety officers.

FSSAI posts updates about these enforcement actions against food business operators and e-commerce companies through social media platforms, including Instagram.

Related Posts

Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

Andelyn bio sciences Inc, a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen’s University to develop and manufacture AAV9-GM2, a gene therapy…

Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

Cellution Biologics Inc, a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

US appeals court sides with Sun Pharma in Lipitor antitrust case

US appeals court sides with Sun Pharma in Lipitor antitrust case

Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad

Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad